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REVIEW CURRENTOPINION Role of the microbiome, probiotics, and ‘dysbiosis
therapy’ in critical illness1070-5295 Copyright  2016 Woltea b cPaul E. Wischmeyer , Daniel McDonald , and Rob KnightPurpose of review
Loss of ‘health-promoting’ microbes and overgrowth of pathogenic bacteria (dysbiosis) in ICU is believed to
contribute to nosocomial infections, sepsis, and organ failure (multiple organ dysfunction syndrome). This
review discusses new understanding of ICU dysbiosis, new data for probiotics and fecal transplantation in
ICU, and new data characterizing the ICU microbiome.
Recent findings
ICU dysbiosis results from many factors, including ubiquitous antibiotic use and overuse. Despite advances
in antibiotic therapy, infections and mortality from often multidrug-resistant organisms (i.e., Clostridium
difficile) are increasing. This raises the question of whether restoration of a healthy microbiome via
probiotics or other ‘dysbiosis therapies’ would be an optimal alternative, or parallel treatment option, to
antibiotics. Recent clinical data demonstrate probiotics can reduce ICU infections and probiotics or fecal
microbial transplant (FMT) can treat Clostridium difficile. This contributes to recommendations that
probiotics should be considered to prevent infection in ICU. Unfortunately, significant clinical variability
limits the strength of current recommendations and further large clinical trials of probiotics and FMT are
needed. Before larger trials of ‘dysbiosis therapy’ can be thoughtfully undertaken, further characterization
of ICU dysbiosis is needed. To addressing this, we conducted an initial analysis demonstrating a rapid
and marked change from a ‘healthy’ microbiome to an often pathogen-dominant microbiota (dysbiosis)
in a broad ICU population.
Summary
A growing body of evidence suggests critical illness and ubiquitous antibiotic use leads to ICU dysbiosis
that is associated with increased ICU infection, sepsis, and multiple organ dysfunction syndrome. Probiotics
and FMT show promise as ICU therapies for infection. We hope future-targeted therapies using microbiome
signatures can be developed to correct ‘illness-promoting’ dysbiosis to restore a healthy microbiome
post-ICU to improve patient outcomes.
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Curr Opin Crit Care 2016, 22:347–353
DOI:10.1097/MCC.0000000000000321INTRODUCTION: ROLE OF THE
MICROBIOME IN HEALTH AND ILLNESS
One of the most exciting scientific advances in
recent years has been the realization that commen-
sal microorganisms (our microbiome) play key roles
in our physiology, including protection against
infection, in drug metabolism, vitamin synthesis,
nutrition, as well as in response to disease. A sur-
prising finding is that disruption of the homeostasis
of the microbiota, known as ‘dysbiosis,’ may be as
vital as host genetics in the development of a range
of diseases, such as inflammatory bowel disease,
obesity, diabetes, and cardiovascular disease. This
suggests that it may be possible to monitor, prevent,
or even cure human disease through regulating
the human microbiota. Recent advances inrs Kluwer Health, Inc. All rights reseculture-independent microbiome DNA sequencing
methods, even in just the last few years, have
resulted in an unprecedented growth in our under-
standing of this vital and dynamic organ. The
medical community has put a large emphasis inrved. www.co-criticalcare.com
KEY POINTS
 Loss of ‘health-promoting’ microbes and overgrowth of
pathogenic bacteria (dysbiosis) in ICU is believed to
contribute to nosocomial infections, sepsis, and organ
failure (multiple organ dysfunction syndrome).
 Recent data indicate as many as 37% of hospital
antibiotic prescriptions are unnecessary or
inappropriately prescribed, further incidence and
mortality from (often antibiotic-resistant) infections like
C. difficile are rising rapidly and optimal alternatives to
antibiotics to treat infection are needed.
 Probiotics show promise to reduce ICU infections and
fecal microbiota transplantation is demonstrating
efficacy to reduce C. difficile colitis; however larger,
targeted trials are needed to define how and who to
best implement ‘dybiosis-therapy’ in.
 Prior to widespread implementation and large clinical
trials of ‘dysbiosis therapy,’ a greater understanding
and characterization of the microbiome changes in the
ICU using culture-independent, amplicon and
metagenomic-based sequencing techniques are needed
in broader ICU populations.
 New initial data from our ongoing ICU microbiome
research reveal a rapid and marked change from a
‘healthy’ microbiome to disrupted microbiota (dysbiosis)
in a broader ICU population.
Metabolic supportthe eradication of microbial life, and in many cases
for good reason. But, perhaps, we should instead
consider how to preserve or reestablish a ‘health-
promoting’ microbiome during and after critical
illness through targeted interventions, such as
probiotics, prebiotics, fecal transplants, and or even
synthetic ‘stool pills’ to improve outcome in
critical illness.IS OUR CURRENT APPROACH TO
INFECTION WORKING?
A great deal of time and effort is spent in eradicating
bacteria and other microbial, fungal, and viral
species in the ICU. The US Centers for Disease
Control reveal 55% of all hospitalized patients
receive an antibiotic during their stay, and in the
ICU, this number increases to 70% of patients.
This observation was confirmed by a recent multi-
national ICU study of more than 14000 patients in
over 1200 ICUs which found that 51% of patients
were considered to be infected on day of survey and
a striking 71% were receiving antibiotics [1]. The
hospital mortality rate of infected patients was
found to be more than twice that of noninfected
patients (33 vs. 15%). Clearly, infection and sepsis
remain a major driver of morbidity and mortality348 www.co-criticalcare.comdespite advances in hospital care and widespread
ICU use antimicrobial therapy [1]. As recently
described by Singer and Gynne [2], it is likely that
this antibiotic use has in part contributed to an
impressive 22-fold fall in crude mortality rates for
infectious diseases in the United States between
1900 and 1980. Yet, it is troubling that mortality
rates from infectious disease (up to 1996) increased
– by 50% – with the septicemia rate nearly doubling
[2]. It remains unclear if the earlier reductions in
mortality and increased life expectancy were due
primarily to antibiotics innovations, or more likely,
because of improved public health and education.
The massive global reliance on antibiotic use
comes at great financial expense with antibiotics
accounting for up to 30% of a hospital’s drug budget
[3]. Unfortunately, the potential risk for patients far
exceeds the financial costs. Evidence suggests that as
many as 37% of antibiotic regimens are unnecessary
or not compliant with guidelines [4
&&
]. This inap-
propriate antibiotic use leads to the emergence of
multidrug resistant bacterial infections; the inci-
dence of these infections is rising rapidly both in
the United States and worldwide [5
&&
]. A recent New
England Journal of Medicine article estimates anti-
biotic-resistant Clostridium difficile occurs now in
more than 450000 patients per year in the United
States alone [5
&&
]. Additionally, these multidrug-
resistant infections are also becoming increasingly
lethal. For example, C. difficile is estimated to con-
tribute to 30000 deaths/year in the United States
[5
&&
,6]. Further, the US Centers for Disease Control
indicates ‘death rates from sepsis following infec-
tions (like C. difficile) have increased at a rate greater
than any other common cause of mortality in the
last year for which data were available’ [7]. And as
stated, this is punctuated by mortality rates from
infectious disease in general (up to 1996) increasing
by 50%, again with the septicemia rate nearly
doubling [2]. Thus, more advanced antibiotics do
not appear to be translating to increased survival
from infectious disease, but instead to increasingly
aggressive resistant organisms and emergence of
increasingly lethal pathogens like C. difficile. ‘Is it
possible we need to rethink our strategy toward
microbial therapy in the ICU?’ANTIBIOTICS KILL MORE THEN JUST
PATHOGENS
These concerns around antibiotics are compounded
by the fact that antibiotics currently used to attempt
to treat infection not only kill pathogens but also
‘health-promoting’ microbes. These adverse effects
include the hypothesized loss of commensal gastro-
intestinal microbiota, which enables overgrowth ofVolume 22  Number 4  August 2016
Microbiome, probiotics, and ‘dysbiosis therapy’ Wischmeyer et al.unwanted organisms (dysbiosis). This may have
significant implications for organs far outside the
gastrointestinal tract as well. The gut has long been
described as the ‘motor’ of systemic inflammatory
response syndrome and of organ failure regardless of
the location of the initial infection [8
&&
]. Thus, the
effect of alterations in the gut microbiota and gut
barrier homeostasis are thought to be transmitted to
and propagated by downstream organs, such as the
spleen and lung where large immune cell popu-
lations are harbored [8
&&
,9,10], leading to inflam-
mation-induced organ failure in the ICU.
At the cellular level, organ failure that ulti-
mately leads to death in the ICU has long been
attributed to mitochondrial failure. It has long been
known that mitochondria trace their evolution
from bacteria that produce energy for our cells.
Recent literature not surprisingly reveals that mito-
chondria are known to be damaged by many of the
antibiotics we commonly administer in the ICU [2].
Thus, we and others hypothesize that antibiotics
may be contributing to organ failure by not only
leading to dysbiosis but also by damaging the very
core of our cells’ energy production [2].Microbiota Microbiome
Human
39 trillion microbial cells
30 trillion human cells
20,000 human genes
2,000,000 microbial genes
43%? 1%?
FIGURE 1. Ratio of microbial to human cells and genes in
human body.IS THERE ANOTHER WAY TO PREVENT
AND TREAT INFECTIONS?
‘Is it possiblewe shouldbegiving ‘‘friendly’’microbes
to our patients, not eradicating them to improve
outcome?’ For young Kaitlin Hunter, microbes were
the best friends she could ever have. As described by
national news reports (http://www.cnn.com/2012/
09/26/health/fecal-transplant/) in 2011, when Kai-
tlinwas only 20 years old, shewas critically injured in
a motor vehicle accident. She recovered from her
injuries after just a month of hospitalization, but
then as she neared returning home she was stricken
with severe, life-threatening C. difficile colitis. Nine
courses of antibiotics failed to treat the aggressive
infection. In desperation, her physicians then turned
to a novel idea: rather than treating the infection
with more antibiotics why not give more bacteria in
the form of a stool transplant from her mother.
Almost immediately, Kaitlin’s C. difficile was cured
and never returned. Was this a miracle or should we
have known this would be successful from the start?
We know now that this was far from an uncommon
miracle as recent data indicate that fecal transplan-
tationhas amore than90%cure rate in even themost
resistant C. difficile colitis cases [11
&
]. How is it
possible that using stool as therapy,whatmostwould
consider unsanitary at best (unethical at worst), is
so effective?
The answer to Kaitlin’s ‘miracle cure’ may lie in
new insights from the study of the microbiome,1070-5295 Copyright  2016 Wolters Kluwer Health, Inc. All rights resewhich is beginning to call into question what
it means to be ‘human.’ Perhaps, our success as a
species is reliant on the trillions of bacterial sym-
biotes we harbor and depend on. It is first important
to recognize that we live in a world dominated by
bacteria [12
&
]. Multicellular lineages like humans are
rare with most of the molecular diversity of life
residing in microbes. Further, what is it that truly
makes us human? Many of us believe it is our cells
that make us human; however, as shown in Fig. 1,
new data show we are made up of as many bacterial
cells as human cells (about a 1 : 1 ratio) [13
&
]. Many
would believe it is our genes that make us human;
however, there are 20000 human genes and an
estimated 2–20 million microbial genes, making us
about 1% human and 99% bacterial based on our
genes alone. Again, this raises the key question that
to fight infection organ failure should we be increas-
ingly focused on treating dysbiosis by restoring a
normal, healthy microbiome in our ICU patients, as
it makes up as much or more of our bodies in health
than our own cells or DNA?THE EVOLVING ROLE FOR PROBIOTICS
AND FECAL TRANSPLANTATION TO
‘RESTORE HEALTH’ IN ILLNESS
More objectively, (as suggested by Loupazone et al.
[14]), perhaps we need to ‘resod’ the lawn that isrved. www.co-criticalcare.com 349
Metabolic supportblighted by critical illness and antibiotics with
probiotics, fecal transplants, and even ‘stool pills’
(see Fig. 2)? This concept is supported at a mecha-
nistic level as described in a number of very recent
and comprehensive review articles [8
&&
,15
&&
]. Alter-
ations in intestinal homeostasis and gut microbiota
in critical illness have been associated with
increased inflammatory cytokine production, gut
barrier dysfunction, and increased cellular apoptosis
all of which can contribute tomultiple organ failure.
To modulate this ‘motor’ of systemic inflammation,
it has been hypothesized that repletion of health-
promoting bacteria via probiotics, prebiotics, stool
transplantation, or combination therapies may be a
promising intervention to maintain gut integrity
and prevent pathologic alterations in the gut
(and other body sites) microbiota or ‘dysbiosis’
[16
&
,17
&
,18
&&
]. Beneficial effects of probiotic inter-
ventions have been shown to include induction
of host cell antimicrobial peptides, release of
antimicrobial factors, suppression of the immune
cell proliferation, stimulation of mucus and IgA
production, antioxidative activity, inhibition of epi-
thelial cell nuclear factor k-B activation, prevention
of gut apoptosis, and other epithelial barrier
protective effects [8
&&
,19
&
,20]. As a result, a growing
number of clinical trials utilizing probiotics, and
even stool transplantation, in critical illness are
being conducted.REVIEW OF CURRENT DATA FOR
PROBIOTIC USE IN CRITICAL ILLNESS
Probiotic use in critical care has recently been the
subject of a number of meta-analyses focused on a
range of outcomes after critical illness. A role for
probiotics in reducing the risk of ICU infection was
initially described by Petrof et al. [21] in 2012. Many
clinical trials and meta-analysis efforts have focused
on the role of reducing ventilator-associatedWe should ‘resod’ the lawn?
Antibiotics
critical illness
Probiotics
stool transplant
‘poop pills’
FIGURE 2. Role of ‘dybiosis therapy’ to restore ‘health-
promoting’ microbiome in critical illness.
350 www.co-criticalcare.compneumonia (VAP). In spite of promising data for
probiotic use in reducing overall infections, the role
of probiotics as a strategy to preventing VAP has
been controversial. In 2010, Siempos et al. [22]
aggregated five probiotic trials demonstrating a
reduction in the incidence of VAP and subsequently,
Barraud et al. [23] also showed a beneficial effect
on ICU-acquired pneumonia. However, in 2012,
Petrof et al. [21] and Wang et al. [24] were unable
to demonstrate a significant effect of probiotics
therapy on VAP. More recently, a Cochrane review
of probiotic therapy specifically for VAP [25
&
], found
with a low quality of evidence that probiotic therapy
is associated with a reduction in the incidence of
VAP. In 2015, an updated meta-analysis from the
Canadian Clinical Practice Guidelines Committee
became available on www.criticalcarenutriton.com.
This analysis evaluated 28 studies of probiotic
therapy in critical care published up to late 2014.
The new results indicate that probiotics continue to
show a significant reduction in infections following
critical illness [relative risk 0.82, 95% confidence
interval (CI) 0.69, 0.97, P¼0.02, heterogeneity
I2¼41%] (see Fig. 3) and a trend to reduction in
VAP (relative risk 0.74, 95% CI 0.55, 1.01, P¼0.06,
heterogeneity I2¼45%). A trend toward a decrease
in ICU length of stay when results of 14 trials were
pooled (weighted mean difference 3.26, 95% CI
7.82, 1.31, P¼0.16, heterogeneity I2¼93%)
although significant statistical heterogeneity was
present in these data. No significant effect on
mortality, hospital length of stay, or other outcomes
was noted. The group noted that these estimates
were found to be sensitive to the quality of the
primary trials. This reduction in infections disap-
peared when only high-quality studies were con-
sidered. Further, the potential for statistical and
clinical heterogeneity indicated that further trials
were needed. Based on this analysis, the Canadian
Clinical Practice Guidelines Committee concluded
that ‘the use of probiotics should be considered
in the critically ill patients.’ As a wide range of
probiotic species and doses were utilized in these
trials, no recommendation could be made for the
dose or a particular type of probiotic, with the
exception of Saccharomyces boulardii, which should
not be used as it is considered unsafe in ICUpatients.
‘However, further large and well designed clinical
trials are needed to strengthen the recommendation
of probiotic use and to confirm these benefits in
critical illness’.
Very recently, a number of new trials of pro-
biotic therapy in critical care have been published
[26
&
,27
&&
] not included in the recent unpublished
CanadianGuidelinesMeta-Analysis. These include a
randomized, controlled multicenter trial by ZengVolume 22  Number 4  August 2016
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FIGURE 3. Effect of probiotic therapy on infection in ICU.
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&&
] involving 235 critically ill adult patients
expected to receive mechanical ventilation for at
least 48h. Patients were randomized to receive
either a probiotics capsule containing live Bacillus
subtilis and Enterococcus faecalis (Medilac-S), 0.5 g
three times daily through a nasogastric feeding tube
plus standard preventive strategies or standard
preventive strategies alone, for a maximum of
14 days. The results revealed the incidence of micro-
biologically confirmed VAP in the probiotics group
was significantly lower than in control patients
(36.4 vs. 50.4%, respectively; P¼0.031). Further,
the mean time to develop VAP was significantly
longer in the probiotics group vs. control (10.4 vs.
7.5 days, respectively; P¼0.022). Future compre-
hensive meta-analysis systematic reviews including
these newer trials are needed.
Focusing on antibiotic-associated diarrhea, a
recent meta-analysis in JAMA showed in 63 studies
and more than 11800 patients that probiotics could
reduce antibiotic-associated diarrhea by 40% [28].
Finally, a recent Cochrane meta-analysis of probi-
otic use in C. difficile colitis and diarrhea demon-
strated that probiotics could reduce C. difficile-
associated diarrhea by 64% in patients taking anti-
biotics (23 studies, n¼4213) [29&&]. Probiotics also
reduced the risk of side-effects associated with
antibiotic use in this analysis.
In addition to probiotic use, fecal transplan-
tation has shown a more than 90% effectiveness
in inducing a cure against C. difficile colitis
[11
&
,30] and ‘stool pills’ alsomay soon show promise
for treating this increasingly aggressive infection.
Finally, a recent case report of successful treatment
of refractory severe sepsis and diarrhea with
fecal transplant has been described [20]. Clinical-
trials.gov currently lists 157 clinical trials that are
planned/completed or underway utilizing fecal1070-5295 Copyright  2016 Wolters Kluwer Health, Inc. All rights resetransplantation (clinicaltrials.gov). Thus, much
more data will soon be available regarding the effi-
cacy of this therapy in multiple conditions.CAN WE DEFINE THE ICU MICROBIOME
(DYSBIOSIS) AND BETTER TARGET OUR
THERAPY?
As stated, critical illness has been hypothesized to
associate with loss of normal, ‘health-promoting’
commensal bacteria (dysbiosis), which might lead
to a high susceptibility to hospital-acquired infec-
tions. Thus, a trial with prospective monitoring
of the ICU microbiome with more comprehensive,
culture-independent techniques to confirm and
characterize this dysbiosis is urgently needed.
Characterization of ICU microbiome changes may
provide first steps in development of diagnostic and
therapeutic interventions using microbiome signa-
tures. Two recent pilot trials have begun to examine
this question. Zaborin et al. [31
&&
] described ICU
microbiome collection in 14 patients. The analysis
focused on four patients with a prolonged length of
ICU stay who showed significant disruption of the
microbial community and the gut microbiota was
shown to consist of ultra-low-diversity communities
of multidrug-resistant pathogenic microbes. A sec-
ond recent 12 patient trial by Ojima et al. [32
&
]
demonstrated changes in Bacteroidetes and Firmi-
cutes may be related to mortality in ICU patients
undergoing fecal microbiome analysis. These initial
findings have led experts and major funding bodies
in the field to conclude that there is urgent need for
larger, more generalizable, prospective studies that
characterize the microbiome in a larger critical care
population to confirm and characterize this poten-
tial dysbiosis and move toward therapeutic inter-
ventions using microbiome signatures [33
&&
].rved. www.co-criticalcare.com 351
PC1 (
PC2 (3.63 %)
PC3 (2.75 %)
Fecal - ICU pts
Fecal - healthy
Oral - healthy
Skin - healthy
Oral - ICU pts
Skin - ICU pts
Microbiome in ICU patients is significantly altered
from healthy subjects
Microbiome of fecal, oral, skin begins to converge in critical illness showing potential
loss of diversity and possible indication of less barrier function.
FIGURE 4. Significant alteration in microbiome in critical
illness vs. health study participants. Microbiome of fecal,
oral, skin begins to converge in critical illness showing
potential loss of diversity and possible indication of loss of
barrier function.
Metabolic supportTHE ICU MICROBIOME PROJECT:
CHARACTERIZING THE DYSBIOSIS OF
CRITICAL ILLNESS
To this end our research group (Wischmeyer et al.)
have begun a collaboration with the Rob Knight Lab
and have recently completed enrollment in an
initial multicenter clinical trial of sequential micro-
biome sampling from ICU patients. To characterize
the ICU microbiome, we collected fecal, oral, and
skin samples from 115 mixed ICU patients across
four centers in the United States and Canada.
Samples were collected at two time points: within
48h of ICU admission, and ICU discharge or ICU
day 10. Sample collection and processing were per-
formed under the Earth Microbiome Project proto-
cols. We are utilizing a large control group of
previously collected healthy controls and environ-
mental surfaces including the AmericanGut Project,
mammalian corpse decomposition samples, child-
hood (Global Gut), and house surfaces. In brief, the
primary control group, the American Gut Project, is
the largest crowd funded citizen science project, and
includes more than 5000 participants, who range
broadly in dietary habits, BMI, activity levels, medi-
cations, and age. For the purposes of our ICUMicro-
biome trial, we included healthy controls free of
chronic disease and without recent antibiotic use.CONCLUSION
Our initial results demonstrate that, when com-
pared with healthy American gut study participants,
critical illness shows rapid and distinct changes
from a ‘healthy’ fecal and oral microbiome
(Fig. 4). Fecal ICU samples tend to have a lower
relative abundance of Firmicutes and increased
relative abundance of Proteobacteria [34
&
]. Large
depletions were observed in organisms shown to
confer anti-inflammatory benefits such as Faecali-
bacterium [35], which specifically is known to pro-
duce short-chain fatty acids that are vital to the gut.
Conversely, many of the taxa which increased con-
tain well recognized pathogens such as Enterobacter
and Staphylococcus. Ongoing analysis will assess
source composition of ICU samples and examine
potential relationship of changes in the ICU micro-
biome to clinical outcome. In summary, our initial
data from the ICU Microbiome Project confirm that
severe dysbiosis occurs in a broad, larger population
of critically ill study participants. These data may
help guide creation of targeted microbial therapies,
focused on correcting potentially ‘illness-promot-
ing’ dysbiosis using specific probiotics or targeted,
multimicrobe ‘stool pills’ to restore a healthy micro-
biome and improve outcomes in critical illness. And352 www.co-criticalcare.comin the end, perhaps this is the beginning of a road to
a better way to treat and prevent infection than the
ubiquitous antibiotics universally given to most all
patients in hospitals and ICUs today!Acknowledgements
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